NZ581710A - Materials and methods for treatment and diagnosis of disorders associated with oxidative stress - Google Patents

Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Info

Publication number
NZ581710A
NZ581710A NZ581710A NZ58171008A NZ581710A NZ 581710 A NZ581710 A NZ 581710A NZ 581710 A NZ581710 A NZ 581710A NZ 58171008 A NZ58171008 A NZ 58171008A NZ 581710 A NZ581710 A NZ 581710A
Authority
NZ
New Zealand
Prior art keywords
ulcerative colitis
hydrogen peroxide
colonic
glutathione
composition
Prior art date
Application number
NZ581710A
Other languages
English (en)
Inventor
Jay Pravda
Original Assignee
Jay Pravda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jay Pravda filed Critical Jay Pravda
Publication of NZ581710A publication Critical patent/NZ581710A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
NZ581710A 2007-06-13 2008-06-13 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress NZ581710A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93450507P 2007-06-13 2007-06-13
US6374508P 2008-02-06 2008-02-06
PCT/US2008/007401 WO2008156671A2 (en) 2007-06-13 2008-06-13 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Publications (1)

Publication Number Publication Date
NZ581710A true NZ581710A (en) 2012-02-24

Family

ID=40156844

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ581710A NZ581710A (en) 2007-06-13 2008-06-13 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Country Status (14)

Country Link
US (2) US8476233B2 (enExample)
EP (2) EP2162125B1 (enExample)
JP (1) JP2010529197A (enExample)
KR (1) KR20100038098A (enExample)
CN (1) CN101707877B (enExample)
AT (1) ATE529105T1 (enExample)
AU (1) AU2008266996A1 (enExample)
BR (1) BRPI0812729A2 (enExample)
CA (1) CA2691132C (enExample)
IL (1) IL202685A0 (enExample)
MX (1) MX2009013683A (enExample)
NZ (1) NZ581710A (enExample)
WO (1) WO2008156671A2 (enExample)
ZA (1) ZA200908828B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
IN2014DN06662A (enExample) * 2012-02-13 2015-05-22 Cosmo Technologies Ltd
US10071058B2 (en) * 2012-03-07 2018-09-11 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
WO2014008273A2 (en) * 2012-07-03 2014-01-09 Jay Pravda Methods for treating, diagnosing and/or monitoring progression of oxo associated states
EP3181120A1 (en) 2012-11-09 2017-06-21 Scidose LLC Enema composition for treatment of ulcerative colitis having long term stability
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
EA201791686A8 (ru) 2015-01-26 2018-10-31 Др. Фальк Фарма Гмбх Клизма для ректального введения
EP3115037B1 (de) 2015-07-08 2018-08-15 Dr. Falk Pharma Gmbh Pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des enddarms
ES2808928T3 (es) * 2015-11-27 2021-03-02 Birrbeheer B V Sales de butirato para uso en enfermedades inflamatorias
US20200049722A1 (en) * 2016-09-26 2020-02-13 Precision Medicine Holdings Pty Ltd Diagnosis, prognosis and treatment for schizophrenia and schizoaffective psychosis
WO2018122086A1 (en) * 2016-12-28 2018-07-05 Dr. Falk Pharma Gmbh Enema for rectal application
CN108034631A (zh) * 2017-12-04 2018-05-15 武汉轻工大学 一种双氧水诱导猪小肠上皮细胞凋亡模型的建立方法
JP2019113375A (ja) * 2017-12-22 2019-07-11 サッポロホールディングス株式会社 腸内環境評価方法、大腸炎罹患リスク評価方法、及び腸内環境改善物質のスクリーニング方法
EP3741368B1 (en) * 2018-01-18 2024-03-06 Keio University Capsule for use in treating ulcerative colitis
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
WO2024026200A1 (en) * 2022-07-27 2024-02-01 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
JP2025066445A (ja) * 2023-10-11 2025-04-23 国立大学法人東北大学 炎症性疾患の治療薬、及び治療薬のスクリーニング方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211777A (en) * 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4657900A (en) * 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
EP0382066A3 (de) 1989-02-09 1992-01-08 ASTA Medica Aktiengesellschaft Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
GB8909559D0 (en) * 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
US5378470A (en) 1989-07-25 1995-01-03 Henning Berlin Gmbh Rectally administered pharmaceutical preparation
JPH03169813A (ja) 1989-11-09 1991-07-23 Asta Pharma Ag 細胞保護作用を有する疼痛及び炎症性疾患及び／又はレトロウイルスに起因する病気の治療用医薬並びにその製法
DE4218572A1 (de) 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US5569670A (en) 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US8178516B2 (en) 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
JP2917799B2 (ja) * 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
US5563131A (en) 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
DE19509806A1 (de) 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
WO1999055326A1 (en) 1998-04-30 1999-11-04 Vit-Immune, L.C. Method of treatment of glutathione deficient mammals
CA2274943A1 (en) * 1998-06-17 1999-12-17 Stephen L. Wolman Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
AR042572A1 (es) 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1172110A3 (de) 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
AU2002256507A1 (en) * 2001-05-09 2002-11-18 Novartis Ag Methods for selective immunomodulation using pimecrolimus
US20030235571A1 (en) 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
WO2004024868A2 (en) 2002-09-10 2004-03-25 National Jewish Medical And Research Center Product and process for liquefaction of mucus or sputum
US7157444B2 (en) 2002-12-21 2007-01-02 Deanna Jean Nelson Aminosalicylate derivatives for treatment of inflammatory bowel disease
DE10305661A1 (de) 2003-02-12 2004-08-26 Degussa Ag Darreichungsform zur Kolon-spezifischen Wirkstofffreisetzung
EP1603556A2 (en) * 2003-03-06 2005-12-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sod mimic multifunctional compounds for treating inflammatory bowel disease
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress

Also Published As

Publication number Publication date
EP2162125B1 (en) 2011-10-19
US20130344184A1 (en) 2013-12-26
ZA200908828B (en) 2010-12-29
BRPI0812729A2 (pt) 2019-02-12
WO2008156671A3 (en) 2009-03-12
US20100184728A1 (en) 2010-07-22
WO2008156671A2 (en) 2008-12-24
MX2009013683A (es) 2010-04-07
CA2691132A1 (en) 2008-12-24
EP2392321A1 (en) 2011-12-07
CN101707877B (zh) 2013-01-09
CA2691132C (en) 2016-01-12
JP2010529197A (ja) 2010-08-26
IL202685A0 (en) 2010-06-30
AU2008266996A1 (en) 2008-12-24
ATE529105T1 (de) 2011-11-15
EP2162125A2 (en) 2010-03-17
US8476233B2 (en) 2013-07-02
CN101707877A (zh) 2010-05-12
KR20100038098A (ko) 2010-04-12
EP2162125A4 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
CA2691132C (en) Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US7312243B1 (en) Materials and methods for treatment of gastrointestinal disorders
US20100112088A1 (en) Materials and methods for treatment of disorders associated with oxidative stress
JP2010529197A5 (enExample)
Sun et al. Mitochondria in sepsis-induced AKI
Pravda Radical induction theory of ulcerative colitis
Sid et al. Role of oxidative stress in the pathogenesis of alcohol-induced liver disease
Papalou et al. Oxidative stress in polycystic ovary syndrome
von Montfort et al. Mitochondrial GSH determines the toxic or therapeutic potential of superoxide scavenging in steatohepatitis
Kang et al. Zinc prevention and treatment of alcoholic liver disease
Dodd et al. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility
Smith et al. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress
Tveden-Nyborg et al. Does vitamin C deficiency increase lifestyle-associated vascular disease progression? Evidence based on experimental and clinical studies
Sarna et al. Tyrosol attenuates high fat diet-induced hepatic oxidative stress: Potential involvement of cystathionine β-synthase and cystathionine γ-lyase
JP2017533969A (ja) Ｎ−アセチルシステインアミドによる網膜色素変性症の治療
McCarty Nutraceutical strategies for ameliorating the toxic effects of alcohol
AU2005211936A1 (en) Alcohol metabolism moderating composition
US10064877B2 (en) Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
Ling et al. Therapeutic implications of nitrite in hypertension
Scheinman et al. IgA nephropathy: to treat or not to treat?
Shalansky et al. N‐acetylcysteine for Prevention of Radiographic Contrast Material–Induced Nephropathy: Is the Intravenous Route Best?
Mitobe et al. The effects of aspirin on antioxidant defences of cultured rat gastric mucosal cells
Albano Oxidative stress in alcoholic liver disease
Seneff et al. Regulation of Melatonin Metabolism by Gut Microbes and the Role of Deuterium
Lopez et al. Atherosclerosis, Mitochondrial Dysfunction and Oxidative Stress: Mitochondria-Targeted Antioxidants as Potential Therapy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2016 BY COMPUTER PACKAGES INC

Effective date: 20150519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2017 BY COMPUTER PACKAGES INC

Effective date: 20160518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20170620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180531

LAPS Patent lapsed